A phase III randomized, placebo-controlled clinical trial to study the safety and efficacy of the addition of sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on combination therapy with metformin and a PPARg [peroxisome proliferator-activated receptor gamma] agonist.

Trial Profile

A phase III randomized, placebo-controlled clinical trial to study the safety and efficacy of the addition of sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on combination therapy with metformin and a PPARg [peroxisome proliferator-activated receptor gamma] agonist.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2017

At a glance

  • Drugs Sitagliptin (Primary) ; Glipizide; Metformin; Rosiglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jul 2009 Actual patient numbers amended from 300 to 262 as reported by ClinicalTrials.gov.
    • 29 Sep 2008 Rosiglitazone, glipizide identified as an additional treatment arm as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top